Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 8/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16605482 | 0.95 | F10 (0.41) | F10ACKR3NOS3NOS1PTAFR | |
| SCHEMBL16603461 | 0.93 | F10 (0.42) | F10NOS3NOS1MTNR1AMTNR1B | |
| SCHEMBL16603474 | 0.88 | IKBKB (0.36) | F10ACKR3NOS3NOS1NQO2 | |
| SCHEMBL15244944 | 0.87 | F10 (0.46) | F10NOS3NOS1MTNR1AMTNR1B | |
| SCHEMBL15245043 | 0.80 | NOS1 (0.38) | NOS3NOS1 | |
| SCHEMBL16605480 | 0.80 | CDK8 (0.39) | F10NOS3NOS1 | |
| SCHEMBL16284389 | 0.79 | F10 (0.43) | F10NOS1MTNR1AMTNR1B | |
| SCHEMBL16603492 | 0.79 | PRSS1 (0.39) | F10PRSS1 | |
| SCHEMBL16169751 | 0.78 | NQO2 (0.39) | NQO2 | |
| SCHEMBL16605481 | 0.78 | MKNK1 (0.41) | F10NOS3NOS1PTAFRPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | PC, CPS1, GLS2 | F10 3742/4885ACKR3 2190/4885NOS3 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.